TrialA Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
Trial details
- Registry ID
- NCT04917874
- Phase
- Phase 3
KRYS
Krystal Biotech, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Long-term Treatment With B-VEC for Dystrophic Epidermolysis BullosaNCT04917874 | KRYS | Phase 3 | Completed | 2023-07-31Actual |
| A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaNCT07016750 | KRYS | Phase 3 | Recruiting | 2026-12Estimated |
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
Trial details
- Registry ID
- NCT07016750
- Phase
- Phase 3
Latest recorded trial changes
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
NCT07016750 · Krystal Biotech, Inc.
Planned enrollment decreased by 4 participants
− Before
20 participants (planned)
+ After
16 participants (planned)
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
NCT07016750 · Krystal Biotech, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: To evaluate the safety and tolerability of KB803.
Measure: To evaluate the effect of ophthalmic KB803 versus placebo on frequency of corneal. abrasion symptoms.
+ After
Measure: To evaluate the safety and tolerability of KB803. Measure: To evaluate the effect of ophthalmic KB803 on frequency of corneal abrasion symptoms.
Planned enrollment increased by 4 participants
− Before
16 participants (planned)
+ After
20 participants (planned)
Primary completion date changed
− Before
Mar 2026
+ After
Dec 2026